CLINICAL TRIAL article
Front. Med.
Sec. Pulmonary Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1574706
Early re-examination of chest CT may be unnecessary when patients with psittaci pneumonia at low and intermediate risk on Pneumonia Severity Index (PSI) present with response to initial treatment
Provisionally accepted
- 1Department of Rehabilitation Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang Province, China
- 2Zhejiang Chinese Medicine University, Hangzhou, China
- 3Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang Province, China
- 4Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Chlamydia parrot pneumonia ( Cps ) is a rare community-acquired pneumonia (CAP) caused by Chlamydia parrot infection. With the development of metagenomic second-generation sequencing technology (mNGS), its diagnostic rate has improved in recent years. However, there are few clinical studies on Chlamydia parrot pneumonia, especially for patients with low and intermediate pneumonia severity index (PSI), and the necessity of early review of chest computed tomography(CT) is not clear. This study aimed to explore the clinical significance of early review of chest CT in patients with low and intermediate risk of Chlamydia parrot pneumonia with PSI after initial treatment was effective. Methods: Retrospective analysis of 8 patients with Chlamydia psittaci pneumonia diagnosed by metagenomic next-generation sequencing (mNGS) admitted to Zhejiang Provincial Tongde Hospital from January 2020 to December 2022 (PSI score ≤ 130 points). All patients had improved clinical symptoms and inflammatory markers after receiving antibiotic treatment, and chest CT was reexamined within 5-12 days. Evaluate the correlation between imaging changes before and after treatment and clinical symptoms and inflammatory indicators (CRP, PCT, WBC, etc.).Results: After treatment, the patient's body temperature, CRP, PCT and other indicators decreased significantly (P<0.05). However, early CT reexamination showed that imaging progressed in 5 cases (62.5%), was stable in 2 cases (25%), and only 1 case (12.5%) showed partial improvement (P > 0.05). Nevertheless, none of the patients had a deterioration in their condition later on and finally achieved imaging recovery.Clinicians did not adjust the treatment plan when imaging progressed, and only 1 case was given glucocorticoid additionally.For patients with low-intermediate risk chlamydia psittaci pneumonia with low PSI, if clinical symptoms and inflammatory markers improve, early reexamination of chest CT may have no additional clinical value and does not affect treatment decisions. Therefore, it is not recommended to routinely perform early CT reexamination for such patients to reduce unnecessary consumption of medical resources.Larger sample studies are needed in the future for further verification.
Keywords: parrot fever, Chlamydia pneumonia, intermediate pneumonia severity index, Chest computed tomography, Inflammatory markers
Received: 11 Feb 2025; Accepted: 29 Apr 2025.
Copyright: © 2025 Chen, Zeng Shuying, jia, miao and qian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhang qing qian, Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou, 310012, Zhejiang Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.